JP2013510321A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013510321A5 JP2013510321A5 JP2012538050A JP2012538050A JP2013510321A5 JP 2013510321 A5 JP2013510321 A5 JP 2013510321A5 JP 2012538050 A JP2012538050 A JP 2012538050A JP 2012538050 A JP2012538050 A JP 2012538050A JP 2013510321 A5 JP2013510321 A5 JP 2013510321A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- hours
- serum creatinine
- assigning
- possibility
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 80
- 229940109239 creatinine Drugs 0.000 claims 40
- 210000002966 serum Anatomy 0.000 claims 40
- 238000000034 method Methods 0.000 claims 36
- 210000002700 urine Anatomy 0.000 claims 31
- 210000001124 body fluid Anatomy 0.000 claims 23
- 230000003907 kidney function Effects 0.000 claims 21
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 16
- 208000033626 Renal failure acute Diseases 0.000 claims 16
- 201000011040 acute kidney failure Diseases 0.000 claims 16
- 208000012998 acute renal failure Diseases 0.000 claims 15
- 238000003556 assay Methods 0.000 claims 15
- 239000010839 body fluid Substances 0.000 claims 11
- 210000003734 kidney Anatomy 0.000 claims 11
- 108060003951 Immunoglobulin Proteins 0.000 claims 10
- 102000018358 immunoglobulin Human genes 0.000 claims 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 10
- 230000006378 damage Effects 0.000 claims 9
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 claims 8
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 claims 8
- 229940072041 transforming growth factor beta 2 Drugs 0.000 claims 8
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 7
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 7
- 108090000613 Cathepsin S Proteins 0.000 claims 7
- 102100035654 Cathepsin S Human genes 0.000 claims 7
- 102000019034 Chemokines Human genes 0.000 claims 7
- 108010012236 Chemokines Proteins 0.000 claims 7
- 102000004318 Matrilysin Human genes 0.000 claims 7
- 108090000855 Matrilysin Proteins 0.000 claims 7
- 101710170091 Transmembrane glycoprotein NMB Proteins 0.000 claims 7
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 claims 7
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 7
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 7
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims 7
- 108010048036 Angiopoietin-2 Proteins 0.000 claims 6
- 102000009075 Angiopoietin-2 Human genes 0.000 claims 6
- 102000000905 Cadherin Human genes 0.000 claims 5
- 108050007957 Cadherin Proteins 0.000 claims 5
- 101710190843 Carcinoembryonic antigen-related cell adhesion molecule 1 Proteins 0.000 claims 5
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims 5
- 102100031506 Complement C5 Human genes 0.000 claims 5
- 108010028773 Complement C5 Proteins 0.000 claims 5
- 102000004420 Creatine Kinase Human genes 0.000 claims 5
- 108010042126 Creatine kinase Proteins 0.000 claims 5
- 102000000802 Galectin 3 Human genes 0.000 claims 5
- 108010001517 Galectin 3 Proteins 0.000 claims 5
- 229920002971 Heparan sulfate Polymers 0.000 claims 5
- 102000004877 Insulin Human genes 0.000 claims 5
- 108090001061 Insulin Proteins 0.000 claims 5
- 102000009073 Macrophage Migration-Inhibitory Factors Human genes 0.000 claims 5
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 claims 5
- 108010076497 Matrix Metalloproteinase 10 Proteins 0.000 claims 5
- 102100036154 Platelet basic protein Human genes 0.000 claims 5
- 101710195957 Platelet basic protein Proteins 0.000 claims 5
- 102000004211 Platelet factor 4 Human genes 0.000 claims 5
- 108090000778 Platelet factor 4 Proteins 0.000 claims 5
- 102100028848 Stromelysin-2 Human genes 0.000 claims 5
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 claims 5
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 claims 5
- 239000012530 fluid Substances 0.000 claims 5
- 229940125396 insulin Drugs 0.000 claims 5
- 239000003153 chemical reaction reagent Substances 0.000 claims 4
- 230000007423 decrease Effects 0.000 claims 4
- 230000003247 decreasing effect Effects 0.000 claims 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 3
- 206010061481 Renal injury Diseases 0.000 claims 3
- 239000000090 biomarker Substances 0.000 claims 3
- 238000003745 diagnosis Methods 0.000 claims 3
- 230000027455 binding Effects 0.000 claims 2
- 230000006870 function Effects 0.000 claims 2
- 238000004393 prognosis Methods 0.000 claims 2
- 238000012959 renal replacement therapy Methods 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 230000002485 urinary effect Effects 0.000 claims 2
- 102000009840 Angiopoietins Human genes 0.000 claims 1
- 108010009906 Angiopoietins Proteins 0.000 claims 1
- 201000003126 Anuria Diseases 0.000 claims 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 claims 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 claims 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims 1
- 102100024649 Cell adhesion molecule 1 Human genes 0.000 claims 1
- 108010078546 Complement C5a Proteins 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 102000001554 Hemoglobins Human genes 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 102100030856 Myoglobin Human genes 0.000 claims 1
- 108010062374 Myoglobin Proteins 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- 229940126575 aminoglycoside Drugs 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 238000007675 cardiac surgery Methods 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 238000012875 competitive assay Methods 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000002296 eclampsia Diseases 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 230000024924 glomerular filtration Effects 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 229910001385 heavy metal Inorganic materials 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- 229960001101 ifosfamide Drugs 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 201000001474 proteinuria Diseases 0.000 claims 1
- 230000002829 reductive effect Effects 0.000 claims 1
- 238000012493 sandwich binding assay Methods 0.000 claims 1
- 238000013517 stratification Methods 0.000 claims 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims 1
- 229960001052 streptozocin Drugs 0.000 claims 1
- 229960001967 tacrolimus Drugs 0.000 claims 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
- 238000007631 vascular surgery Methods 0.000 claims 1
Applications Claiming Priority (45)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25913609P | 2009-11-07 | 2009-11-07 | |
| US25915709P | 2009-11-07 | 2009-11-07 | |
| US25915909P | 2009-11-07 | 2009-11-07 | |
| US25915309P | 2009-11-07 | 2009-11-07 | |
| US25915609P | 2009-11-07 | 2009-11-07 | |
| US25914809P | 2009-11-07 | 2009-11-07 | |
| US25916109P | 2009-11-07 | 2009-11-07 | |
| US25913509P | 2009-11-07 | 2009-11-07 | |
| US25915209P | 2009-11-07 | 2009-11-07 | |
| US25914509P | 2009-11-07 | 2009-11-07 | |
| US25915109P | 2009-11-07 | 2009-11-07 | |
| US25915509P | 2009-11-07 | 2009-11-07 | |
| US25916209P | 2009-11-07 | 2009-11-07 | |
| US25913909P | 2009-11-07 | 2009-11-07 | |
| US25916009P | 2009-11-07 | 2009-11-07 | |
| US25914709P | 2009-11-07 | 2009-11-07 | |
| US25913709P | 2009-11-07 | 2009-11-07 | |
| US61/259,156 | 2009-11-07 | ||
| US61/259,139 | 2009-11-07 | ||
| US61/259,136 | 2009-11-07 | ||
| US61/259,157 | 2009-11-07 | ||
| US61/259,162 | 2009-11-07 | ||
| US61/259,159 | 2009-11-07 | ||
| US61/259,148 | 2009-11-07 | ||
| US61/259,137 | 2009-11-07 | ||
| US61/259,160 | 2009-11-07 | ||
| US61/259,152 | 2009-11-07 | ||
| US61/259,161 | 2009-11-07 | ||
| US61/259,147 | 2009-11-07 | ||
| US61/259,135 | 2009-11-07 | ||
| US61/259,153 | 2009-11-07 | ||
| US61/259,151 | 2009-11-07 | ||
| US61/259,145 | 2009-11-07 | ||
| US61/259,155 | 2009-11-07 | ||
| US28592909P | 2009-12-11 | 2009-12-11 | |
| US28592809P | 2009-12-11 | 2009-12-11 | |
| US61/285,928 | 2009-12-11 | ||
| US61/285,929 | 2009-12-11 | ||
| US32072310P | 2010-04-03 | 2010-04-03 | |
| US61/320,723 | 2010-04-03 | ||
| US34655110P | 2010-05-20 | 2010-05-20 | |
| US34654710P | 2010-05-20 | 2010-05-20 | |
| US61/346,551 | 2010-05-20 | ||
| US61/346,547 | 2010-05-20 | ||
| PCT/US2010/055721 WO2011057138A1 (en) | 2009-11-07 | 2010-11-05 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016181599A Division JP6609533B2 (ja) | 2009-11-07 | 2016-09-16 | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013510321A JP2013510321A (ja) | 2013-03-21 |
| JP2013510321A5 true JP2013510321A5 (enExample) | 2013-12-12 |
Family
ID=43970376
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012538050A Pending JP2013510321A (ja) | 2009-11-07 | 2010-11-05 | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
| JP2016181599A Expired - Fee Related JP6609533B2 (ja) | 2009-11-07 | 2016-09-16 | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016181599A Expired - Fee Related JP6609533B2 (ja) | 2009-11-07 | 2016-09-16 | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP3153863B1 (enExample) |
| JP (2) | JP2013510321A (enExample) |
| CN (2) | CN104914247B (enExample) |
| AU (2) | AU2010314999B2 (enExample) |
| CA (1) | CA2779905A1 (enExample) |
| EA (1) | EA201290195A1 (enExample) |
| MX (1) | MX2012005210A (enExample) |
| NZ (2) | NZ624614A (enExample) |
| WO (1) | WO2011057138A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103988076A (zh) * | 2011-08-12 | 2014-08-13 | 阿尔弗雷德医疗集团 | 包括测量巨噬细胞移动抑制因子（mif）的血浆浓度的诊断、预后或治疗急性冠状动脉综合征（acs）的方法 |
| WO2013096740A1 (en) * | 2011-12-21 | 2013-06-27 | Alere San Diego Inc. | Methods and compositions for assigning likelihood of chronic kidney disease progression |
| MX388231B (es) | 2014-10-20 | 2025-03-19 | Astute Medical Inc | Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal. |
| CA3012985A1 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
| CA3008495A1 (en) | 2015-12-18 | 2017-06-22 | Talengen International Limited | Method for preventing and treating cervical erosion |
| WO2017101873A1 (zh) | 2015-12-18 | 2017-06-22 | 深圳瑞健生命科学研究院有限公司 | 一种预防或治疗放射性和化学性损伤的方法 |
| CN107345968A (zh) * | 2016-05-05 | 2017-11-14 | 中国医学科学院基础医学研究所 | Cecam1蛋白作为血清标记物在诊断肝脏疾病中的用途 |
| CN108210894A (zh) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | 预防和治疗病理性肾组织损伤的药物及其用途 |
| CN110114080A (zh) | 2016-12-15 | 2019-08-09 | 泰伦基国际有限公司 | 一种预防和治疗皮肤纤维化的方法 |
| EP4063853A1 (en) | 2017-01-12 | 2022-09-28 | Astute Medical, Inc. | Methods and compositions for evaluation and treatment of renal injury and renal failure based on c-c motif chemokine ligand 14 measurement |
| TWI714862B (zh) | 2017-06-19 | 2021-01-01 | 大陸商深圳瑞健生命科學硏究院有限公司 | 一種調控glp-1/glp-1r的方法和藥物 |
| EP4071480A1 (en) * | 2021-04-09 | 2022-10-12 | Fundació Ace. Institut Català de Neurociències Aplicades | Cerebrospinal fluid biomarker for alzheimer's disease |
| WO2024040225A2 (en) * | 2022-08-19 | 2024-02-22 | The Johns Hopkins University | Diagnosis and treatment of acute kidney injury |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5939272A (en) | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
| US5028535A (en) | 1989-01-10 | 1991-07-02 | Biosite Diagnostics, Inc. | Threshold ligand-receptor assay |
| US5922615A (en) | 1990-03-12 | 1999-07-13 | Biosite Diagnostics Incorporated | Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network |
| WO1992005282A1 (en) | 1990-09-14 | 1992-04-02 | Biosite Diagnostics, Inc. | Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays |
| US5955377A (en) | 1991-02-11 | 1999-09-21 | Biostar, Inc. | Methods and kits for the amplification of thin film based assays |
| ATE177841T1 (de) | 1991-04-10 | 1999-04-15 | Biosite Diagnostics Inc | ''crosstalk''- oder übersprech-inhibitoren und ihre verwendung |
| EP0579767B1 (en) | 1991-04-11 | 2000-08-23 | Biosite Diagnostics Inc. | Novel conjugates and assays for simultaneous detection of multiple ligands |
| US6143576A (en) | 1992-05-21 | 2000-11-07 | Biosite Diagnostics, Inc. | Non-porous diagnostic devices for the controlled movement of reagents |
| US5885527A (en) | 1992-05-21 | 1999-03-23 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membrances |
| US5494829A (en) | 1992-07-31 | 1996-02-27 | Biostar, Inc. | Devices and methods for detection of an analyte based upon light interference |
| US5824799A (en) | 1993-09-24 | 1998-10-20 | Biosite Diagnostics Incorporated | Hybrid phthalocyanine derivatives and their uses |
| US6113855A (en) | 1996-11-15 | 2000-09-05 | Biosite Diagnostics, Inc. | Devices comprising multiple capillarity inducing surfaces |
| US5947124A (en) | 1997-03-11 | 1999-09-07 | Biosite Diagnostics Incorporated | Diagnostic for determining the time of a heart attack |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| JP2007078705A (ja) * | 1997-04-04 | 2007-03-29 | Seikagaku Kogyo Co Ltd | ヘパラン硫酸の定量方法及び定量キット |
| AU1674400A (en) * | 1998-12-21 | 2000-07-12 | Monash University | Kidney disease detection and treatment |
| EP1282823B1 (en) * | 2000-05-17 | 2014-05-07 | Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO | Proteolytic enzymes for the diagnosis of kidney disorders |
| US20030003588A1 (en) * | 2001-06-28 | 2003-01-02 | Comper Wayne D. | Method for kidney disease detection by protein profiling |
| US7560244B2 (en) * | 2003-06-04 | 2009-07-14 | Joslin Diabetes Center, Inc. | Method of evaluating a subject for risk or predisposition of reduced renal function over time |
| ATE476994T1 (de) * | 2004-11-30 | 2010-08-15 | Curagen Corp | Antikörper gegen gpnmb und ihre verwendungen |
| EP1808694A1 (en) * | 2006-01-17 | 2007-07-18 | Universitätsklinikum Freiburg | Method for diagnosing polycystic kidney disease |
| WO2008133641A2 (en) * | 2006-10-11 | 2008-11-06 | Curagen Corporation | Antibodies directed to gpnmb and uses thereof |
| JP2008118915A (ja) * | 2006-11-10 | 2008-05-29 | Kazuto Nishio | 胃癌高発現遺伝子特定による胃癌診断および創薬への利用 |
| EP2095107B1 (en) * | 2006-11-14 | 2014-07-02 | Alere San Diego, Inc. | Methods for risk assignment |
| NZ628843A (en) * | 2008-10-21 | 2016-02-26 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US8460884B2 (en) * | 2008-11-05 | 2013-06-11 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Use of hematopoietic growth factor inducible neurokinin-1 (HGFIN) as a biomarker for renal injury or renal disease |
-
2010
- 2010-11-05 MX MX2012005210A patent/MX2012005210A/es not_active Application Discontinuation
- 2010-11-05 AU AU2010314999A patent/AU2010314999B2/en not_active Ceased
- 2010-11-05 CN CN201510259537.4A patent/CN104914247B/zh not_active Expired - Fee Related
- 2010-11-05 JP JP2012538050A patent/JP2013510321A/ja active Pending
- 2010-11-05 NZ NZ624614A patent/NZ624614A/en not_active IP Right Cessation
- 2010-11-05 CN CN201080057014.7A patent/CN102711827B/zh not_active Expired - Fee Related
- 2010-11-05 WO PCT/US2010/055721 patent/WO2011057138A1/en not_active Ceased
- 2010-11-05 EP EP16196505.8A patent/EP3153863B1/en active Active
- 2010-11-05 EA EA201290195A patent/EA201290195A1/ru unknown
- 2010-11-05 NZ NZ600160A patent/NZ600160A/en not_active IP Right Cessation
- 2010-11-05 EP EP10829191.5A patent/EP2496258B1/en not_active Not-in-force
- 2010-11-05 CA CA2779905A patent/CA2779905A1/en not_active Abandoned
-
2014
- 2014-09-12 AU AU2014224137A patent/AU2014224137A1/en not_active Abandoned
-
2016
- 2016-09-16 JP JP2016181599A patent/JP6609533B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013510321A5 (enExample) | ||
| JP2014529073A5 (enExample) | ||
| JP2013519095A5 (enExample) | ||
| JP2016505143A5 (enExample) | ||
| JP2013510322A5 (enExample) | ||
| JP2013531240A5 (enExample) | ||
| JP2012517594A5 (enExample) | ||
| JP2014521088A5 (enExample) | ||
| JP5444363B2 (ja) | 慢性腎疾患における予後判定の方法 | |
| US9551720B2 (en) | Urine biomarkers for prediction of recovery after acute kidney injury: proteomics | |
| JP2013539861A5 (enExample) | ||
| HRP20160733T1 (hr) | Postupci i pripravci za postavljanje dijagnoze i prognoze ozljede bubrega i bubrežne insuficijencije | |
| TR201807542T4 (tr) | Böbrek hasarı ve böbrek yetmezliği teşhisi ve prognozuna yönelik metotlar ve bileşimler. | |
| JP2013539030A5 (enExample) | ||
| JP2012517592A5 (enExample) | ||
| JP2013519866A5 (enExample) | ||
| JP2021039112A5 (enExample) | ||
| EP2788759A1 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| HK1222455A1 (zh) | 用於肾损伤和肾衰竭的诊断及预後的方法和组合物 | |
| JP2017533427A5 (enExample) | ||
| AU2017277305A1 (en) | Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2 | |
| JP2012517593A5 (enExample) | ||
| JP2015129764A5 (enExample) | ||
| JP2015508181A5 (enExample) | ||
| JP2017534874A5 (enExample) |